What is beta-oxidation?
Beta-oxidation is the mitochondrial pathway that breaks fatty acids into acetyl-CoA. This page covers its definition, the enzymes involved, and research findings from animal and in vitro studies.
What is beta-oxidation?
Beta-oxidation is the catabolic process by which fatty acid molecules are broken down in the mitochondria to generate acetyl-CoA, NADH, and FADH2. The formal name is β-oxidation (beta-oxidation), also known as the fatty acid oxidation cycle. It is a central pathway of lipid metabolism, distinct from ketogenesis and lipogenesis. The pathway does not have a single molecular formula or sequence; it comprises a series of enzymatic reactions. The overall stoichiometry for the complete oxidation of a saturated fatty acid with n carbons is: Cn-acyl-CoA + (n/2 - 1) FAD + (n/2 - 1) NAD+ + (n/2 - 1) CoA + (n/2 - 1) H2O → (n/2) acetyl-CoA + (n/2 - 1) FADH2 + (n/2 - 1) NADH + (n/2 - 1) H+. No single molecular weight applies to the pathway as a whole.
The work centres on the mitochondrial fatty acid β-oxidation spiral and its associated enzymes, including acyl-CoA dehydrogenases, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase.
Research Studies
GHRP-6 and cardiac function in a rat model of permanent coronary ligation
In a study using rats, GHRP-6 (a growth hormone secretagogue hexapeptide) was administered at 0.4 mg/kg, a dose previously determined as the minimum effective dose for enhancing inotropy in healthy rats. The study employed a non-reperfusion myocardial infarct model via permanent left descending coronary artery ligation. Rats were assigned to sham-operated/normal, infarcted + saline-treated control, and infarcted + GHRP-6 groups. Treatments began post-surgery and continued for 7 days. The study reported that GHRP-6 ameliorated post-infarct ventricular remodeling and systolic dysfunction [1]. While this study does not directly investigate beta-oxidation, it provides an example of research into cardiac energy metabolism and function in an animal model.
Ergogenic supplements and skeletal muscle energy metabolism in cyclists
A comprehensive review of the physiology and evidence base for ergogenic and medical supplements in cycling performance summarized that direct enhancement with ergogenic supplements is primarily achieved via modulation of skeletal muscle energy metabolism. During exercise, adenosine triphosphate (ATP) resynthesis is supported by pathways including beta-oxidation. The review was informed by a structured literature search in PubMed, Scopus, and Web of Science for peer-reviewed studies published up to May 2025, including human participants and evaluating outcomes related to endurance performance, recovery, or physiological function [2]. This review provides context for the role of beta-oxidation in human exercise metabolism.
PYY3-36 and semaglutide-mediated mitochondrial modulation in MASLD
In a study with obese rats, the effects of PYY3-36 on semaglutide-mediated mitochondrial modulation were investigated in the context of metabolic dysfunction-associated steatotic liver disease (MASLD). The study examined cellular effects of the glucagon-like peptide 1 receptor (GLP-1R) and reported that PYY3-36 potentiates semaglutide-mediated mitochondrial modulation [3]. This research is relevant to understanding mitochondrial function, including beta-oxidation, in liver tissue, though it is an animal study and does not directly measure beta-oxidation.
Comparative aspects of beta-oxidation across tissues and models
Beta-oxidation occurs in multiple tissues, with varying rates and regulatory mechanisms. The table below summarizes key features based on the evidence provided.
| Feature | Animal models (rats) | Human studies (review) |
|---|---|---|
| Primary tissue | Heart, liver | Skeletal muscle |
| Intervention | GHRP-6, PYY3-36 + semaglutide | Ergogenic supplements |
| Outcome | Cardiac function, mitochondrial modulation | Endurance performance, ATP resynthesis |
| Reference | [1], [3] | [2] |
Note: The evidence block does not provide direct measurements of beta-oxidation rates or enzyme activities; the studies cited are related to mitochondrial and metabolic function but do not focus exclusively on beta-oxidation.
GHRP-6 and inotropy in healthy rats
In healthy rats, a dose of 0.4 mg/kg GHRP-6 was determined as the minimum effective dose for enhancing inotropy based on echocardiographic parameters [1]. This finding is from an animal study and does not directly address beta-oxidation, but it contributes to understanding cardiac energetics.
Ergogenic supplements and ATP resynthesis in human cyclists
The review of ergogenic supplements for cycling performance indicates that during exercise, ATP resynthesis is supported by multiple pathways, including beta-oxidation. The review included human participants and evaluated outcomes related to endurance performance, recovery, or physiological function [2]. This provides human-relevant context for the role of beta-oxidation in endurance exercise.
PYY3-36 and GLP-1 receptor mechanisms in obese rats
In obese rats with MASLD, PYY3-36 was found to potentiate semaglutide-mediated mitochondrial modulation. The study investigated cellular effects of the GLP-1 receptor [3]. This is an animal study and does not directly measure beta-oxidation, but it relates to mitochondrial function in liver tissue.
Beta-oxidation in cardiac tissue: insights from animal models
Cardiac tissue relies heavily on beta-oxidation for ATP production. In the rat model of permanent coronary ligation, GHRP-6 treatment for 7 days ameliorated post-infarct ventricular remodeling and systolic dysfunction [1]. While beta-oxidation was not directly measured, this study highlights the importance of cardiac energy metabolism in heart failure models.
Beta-oxidation in skeletal muscle: insights from human studies
In human cyclists, ergogenic supplements that modulate skeletal muscle energy metabolism can enhance performance. The review notes that ATP resynthesis during exercise involves beta-oxidation [2]. This is a human study, providing direct relevance to human physiology, though it does not isolate beta-oxidation as the sole mechanism.
Beta-oxidation in liver: insights from animal models of MASLD
In obese rats with MASLD, the combination of PYY3-36 and semaglutide modulated mitochondrial function [3]. Beta-oxidation is a key mitochondrial pathway in the liver, and this study suggests that incretin-based therapies may influence it, though direct measurements are lacking.
If you are reading this for personal health reasons
The compounds and pathways discussed here are for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation
- [2] A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance
- [3] PYY3-36 potentiates semaglutide-mediated mitochondrial modulation in MASLD